Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sugar recognition by human galactokinase.

David J Timson1, Richard J Reece

  • 1School of Biological Sciences, The University of Manchester, 2,205 Stopford Building, Oxford Road, Manchester M13 9PT, United Kingdom. d.timson@qub.ac.uk

BMC Biochemistry
|November 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triosephosphate isomerase from Fasciola hepatica: high-resolution crystal structure as a drug target.

Acta crystallographica. Section F, Structural biology communications·2025
Same author

Galactose epimerase deficiency: lessons from the GalNet registry.

Orphanet journal of rare diseases·2022
Same author

Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1.

Journal of personalized medicine·2022
Same author

Expression, purification and crystallization of a novel metagenome-derived salicylaldehyde dehydrogenase from Alpine soil.

Acta crystallographica. Section F, Structural biology communications·2022
Same author

[<sup>13</sup>C]-galactose breath test in a patient with galactokinase deficiency and spastic diparesis.

JIMD reports·2021
Same author

Galactosemia: Towards Pharmacological Chaperones.

Journal of personalized medicine·2021
Same journal

Application of WST-8 based colorimetric NAD(P)H detection for quantitative dehydrogenase assays.

BMC biochemistry·2019
Same journal

Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.

BMC biochemistry·2019
Same journal

The active role of the transcription factor Sp1 in NFATc2-mediated gene regulation in pancreatic cancer.

BMC biochemistry·2019
Same journal

Role of the highly conserved G68 residue in the yeast phosphorelay protein Ypd1: implications for interactions between histidine phosphotransfer (HPt) and response regulator proteins.

BMC biochemistry·2019
Same journal

Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-κB signalling.

BMC biochemistry·2018
Same journal

Soluble expression of recombinant midgut zymogen (native propeptide) proteases from the Aedes aegypti Mosquito Utilizing E. coli as a host.

BMC biochemistry·2018
See all related articles

Human galactokinase

Area of Science:

  • Biochemistry
  • Enzymology
  • Metabolic pathways

Background:

  • Galactokinase (GALK) catalyzes the initial phosphorylation of galactose.
  • Inhibition of GALK is a potential therapeutic strategy for classical galactosemia.
  • Human GALK exhibits specific substrate recognition crucial for inhibitor design.

Purpose of the Study:

  • Investigate the substrate specificity of human galactokinase.
  • Determine the kinetic effects of mutations in the enzyme's sugar-binding site.
  • Enhance understanding of substrate recognition for therapeutic inhibitor development.

Main Methods:

  • Recombinant human galactokinase expression and purification from E. coli.
  • Site-directed mutagenesis of key residues in the sugar-binding pocket.

Related Experiment Videos

  • Enzyme kinetics assays to determine substrate specificity and kinetic parameters.

    • Main Results:

    • Human galactokinase phosphorylates D-galactose and 2-deoxy-D-galactose but not other tested sugars.
    • Mutating glutamate-43 to alanine had minor effects, while mutation to glycine significantly reduced turnover.
    • Mutations of histidine-44 resulted in protein insolubility, and alterations at aspartate-46 led to inactive enzyme.

    Conclusions:

    • Human galactokinase tolerates modifications at sugar position 2 but not at positions 4 or 6.
    • Experimental mutagenesis data provided insights not predictable from crystal structure alone.
    • Understanding these interactions is vital for designing specific inhibitors for galactosemia.